Hypoxia in head and neck cancer.

A high level of hypoxia in solid tumours is an adverse prognostic factor for the poor outcome of cancer patients following treatment. This review describes the status of research into finding a practical method for measuring hypoxia and treating hypoxic tumours. The application of such methodology would enable the selection of head and neck cancer treatment based on an individual's tumour oxygenation status. This individualization would include the selection not only of surgery or radiotherapy, but also of novel hypoxia-modification strategies.

[1]  David L Buckley,et al.  Prediction of radiotherapy outcome using dynamic contrast enhanced MRI of carcinoma of the cervix. , 2002, International journal of radiation oncology, biology, physics.

[2]  Peter Bartenstein,et al.  Overexpression of Glut‐1 and increased glucose metabolism in tumors are associated with a poor prognosis in patients with oral squamous cell carcinoma , 2003, Cancer.

[3]  J. Bussink,et al.  ARCON: a novel biology-based approach in radiotherapy. , 2002, The Lancet. Oncology.

[4]  A. Harris,et al.  GLUT‐1 and CAIX as intrinsic markers of hypoxia in carcinoma of the cervix: Relationship to pimonidazole binding , 2003, International journal of cancer.

[5]  Quynh-Thu Le,et al.  Identification of osteopontin as a prognostic plasma marker for head and neck squamous cell carcinomas. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[6]  S Osman,et al.  In vivo evaluation of [18F]fluoroetanidazole as a new marker for imaging tumour hypoxia with positron emission tomography , 2004, British Journal of Cancer.

[7]  P Vaupel,et al.  Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix. , 1996, Cancer research.

[8]  Jens Overgaard,et al.  Measurements of hypoxia using pimonidazole and polarographic oxygen-sensitive electrodes in human cervix carcinomas. , 2003, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[9]  P. Vaupel.  Oxygen transport in tumors: characteristics and clinical implications. , 1996, Advances in Experimental Medicine and Biology.

[10]  B. S. Sørensen,et al.  Influence of oxygen concentration and pH on expression of hypoxia induced genes. , 2005, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[11]  E. Leung,et al.  Gene transfer of antisense hypoxia inducible factor-1 α enhances the therapeutic efficacy of cancer immunotherapy , 2001, Gene Therapy.

[12]  J P Logue,et al.  Tumour oxygenation levels correlate with dynamic contrast-enhanced magnetic resonance imaging parameters in carcinoma of the cervix. , 2000, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[13]  C. Grau,et al.  Effect of etoposide, carmustine, vincristine, 5-fluorouracil, or methotrexate on radiobiologically oxic and hypoxic cells in a C3H mouse mammary carcinoma in situ , 2004, Cancer Chemotherapy and Pharmacology.

[14]  C. Rübe,et al.  Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial , 2003, The Lancet.

[15]  T L Phillips,et al.  Oxygen in human tumors: correlations between methods of measurement and response to therapy. Summary of a workshop held November 19-20, 1992, at the National Cancer Institute, Bethesda, Maryland. , 1993, Radiation research.

[16]  D. Harpole,et al.  Correlation of FDG-PET imaging with Glut-1 and Glut-3 expression in early-stage non-small cell lung cancer. , 2001, Lung cancer.

[17]  J. Overgaard,et al.  Pretreatment oxygenation predicts radiation response in advanced squamous cell carcinoma of the head and neck. , 1996, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[18]  F. Ismail-Beigi,et al.  Stimulation of Glucose Transport by Hypoxia: Signals and Mechanisms. , 1999, News in physiological sciences : an international journal of physiology produced jointly by the International Union of Physiological Sciences and the American Physiological Society.

[19]  J. Pouysségur,et al.  Angiogenesis: how a tumor adapts to hypoxia. , 1999, Biochemical and biophysical research communications.

[20]  P Lambin,et al.  Hypoxia as a target for combined modality treatments. , 2002, European journal of cancer.

[21]  D. Brizel,et al.  Prognostic value of tumor oxygenation in 397 head and neck tumors after primary radiation therapy. An international multi-center study. , 2005, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[22]  J. C. Mottram,et al.  A Factor of Importance in the Radio Sensitivity of Tumours , 1936 .

[23]  D. McLaren,et al.  The comet assay in clinical practice. , 1999, Acta oncologica.

[24]  Tove Grönroos,et al.  Imaging perfusion and hypoxia with PET to predict radiotherapy response in head-and-neck cancer. , 2004, International Journal of Radiation Oncology, Biology, Physics.

[25]  B. Branstetter,et al.  Current use of 18F‐Fluorodeoxyglucose Positron Emission Tomography and Combined Positron Emission Tomography and Computed Tomography in Squamous Cell Carcinoma of the Head and Neck , 2005, The Laryngoscope.

[26]  R. Airley,et al.  Glucose transporter glut-1 expression correlates with tumor hypoxia and predicts metastasis-free survival in advanced carcinoma of the cervix. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[27]  David E. Housman,et al.  Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours , 1996, Nature.

[28]  S. Philip,et al.  Osteopontin Stimulates Tumor Growth and Activation of Promatrix Metalloproteinase-2 through Nuclear Factor-κB-mediated Induction of Membrane Type 1 Matrix Metalloproteinase in Murine Melanoma Cells* , 2001, The Journal of Biological Chemistry.

[29]  J. Rüschoff,et al.  Glucose transporter 1 gene expression is related to thyroid neoplasms with an unfavorable prognosis: an immunohistochemical study. , 2002, Thyroid : official journal of the American Thyroid Association.

[30]  R. Fisher,et al.  Tirapazamine, Cisplatin, and Radiation versus Fluorouracil, Cisplatin, and Radiation in patients with locally advanced head and neck cancer: a randomized phase II trial of the Trans-Tasman Radiation Oncology Group (TROG 98.02). , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  J. Overgaard,et al.  Plasma osteopontin, hypoxia, and response to the hypoxia sensitiser nimorazole in radiotherapy of head and neck cancer: results from the DAHANCA 5 randomised double-blind placebo-controlled trial. , 2005, The Lancet. Oncology.

[32]  Johan Bussink,et al.  Pimonidazole binding and tumor vascularity predict for treatment outcome in head and neck cancer. , 2002, Cancer research.

[33]  L. H. Gray,et al.  The Histological Structure of Some Human Lung Cancers and the Possible Implications for Radiotherapy , 1955, British Journal of Cancer.

[34]  J. Kaanders,et al.  ARCON: experience in 215 patients with advanced head-and-neck cancer. , 2001, International journal of radiation oncology, biology, physics.

[35]  N S Thakker,et al.  Prognostic value of facilitative glucose transporter Glut-1 in oral squamous cell carcinomas treated by surgical resection; results of EORTC Translational Research Fund studies. , 2004, European journal of cancer.

[36]  M. Dewhirst,et al.  Oxygenation of head and neck cancer: changes during radiotherapy and impact on treatment outcome. , 1999, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[37]  D. Bloch,et al.  Comparison of the comet assay and the oxygen microelectrode for measuring tumor oxygenation in head-and-neck cancer patients. , 2003, International journal of radiation oncology, biology, physics.

[38]  M. Tian,et al.  Expression of Glut-1 and Glut-3 in untreated oral squamous cell carcinoma compared with FDG accumulation in a PET study , 2003, European Journal of Nuclear Medicine and Molecular Imaging.

[39]  A. Wree,et al.  Microregional Expression of Glucose Transporter-1 and Oxygenation Status: Lack of Correlation in Locally Advanced Cervical Cancers , 2005, Clinical Cancer Research.

[40]  A. Harris,et al.  Carbonic anhydrase IX, an endogenous hypoxia marker, expression in head and neck squamous cell carcinoma and its relationship to hypoxia, necrosis, and microvessel density. , 2001, Cancer research.

[41]  Mark A Mintun,et al.  Assessing tumor hypoxia in cervical cancer by positron emission tomography with 60Cu-ATSM: relationship to therapeutic response-a preliminary report. , 2003, International journal of radiation oncology, biology, physics.

[42]  P. Vaupel.  Oxygen Transport in Tumors , 1996 .

[43]  K. Miura,et al.  Prognostic value of glucose transporter 1 expression in patients with hypopharyngeal carcinoma. , 2002, Anticancer research.

[44]  G. Hanks,et al.  Single-photon emission computed tomography and positron-emission tomography assays for tissue oxygenation. , 2001, Seminars in radiation oncology.

[45]  A. Harris,et al.  Carbonic anhydrase (CA IX) expression, a potential new intrinsic marker of hypoxia: correlations with tumor oxygen measurements and prognosis in locally advanced carcinoma of the cervix. , 2001, Cancer research.

[46]  Raleigh,et al.  Measuring Tumor Hypoxia. , 1996, Seminars in radiation oncology.

[47]  A. Harris,et al.  Endogenous markers of two separate hypoxia response pathways (hypoxia inducible factor 2 alpha and carbonic anhydrase 9) are associated with radiotherapy failure in head and neck cancer patients recruited in the CHART randomized trial. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[48]  H Baddeley,et al.  Dynamic contrast enhanced magnetic resonance scanning as a predictor of response to accelerated radiotherapy for advanced head and neck cancer. , 1999, The British journal of radiology.

[49]  J. Overgaard,et al.  A phase I clinical study of Nimorazole as a hypoxic radiosensitizer. , 1984, International journal of radiation oncology, biology, physics.

[50]  D. Gandara,et al.  Tirapazamine: prototype for a novel class of therapeutic agents targeting tumor hypoxia. , 2002, Seminars in oncology.

[51]  T. Kwok,et al.  Hypoxia-induced drug resistance: comparison to P-glycoprotein-associated drug resistance. , 1991, British Journal of Cancer.

[52]  C. Bokemeyer,et al.  Efficacy of cytotoxic agents used in the treatment of testicular germ cell tumours under normoxic and hypoxic conditions in vitro , 2003, British Journal of Cancer.

[53]  J. Horiot,et al.  ARCON: accelerated radiotherapy with carbogen and nicotinamide in head and neck squamous cell carcinomas. The experience of the Co-operative group of radiotherapy of the european organization for research and treatment of cancer (EORTC). , 2000, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[54]  A. Harris,et al.  Coexpression of hypoxia-inducible factors 1alpha and 2alpha, carbonic anhydrase IX, and vascular endothelial growth factor in nasopharyngeal carcinoma and relationship to survival. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[55]  L. Bastholt,et al.  A randomized double-blind phase III study of nimorazole as a hypoxic radiosensitizer of primary radiotherapy in supraglottic larynx and pharynx carcinoma. Results of the Danish Head and Neck Cancer Study (DAHANCA) Protocol 5-85. , 1998, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[56]  F. Watzinger,et al.  Impact of hemoglobin level and use of recombinant erythropoietin on efficacy of preoperative chemoradiation therapy for squamous cell carcinoma of the oral cavity and oropharynx. , 2001, International journal of radiation oncology, biology, physics.

[57]  R L Wahl,et al.  Intratumoral distribution of tritiated-FDG in breast carcinoma: correlation between Glut-1 expression and FDG uptake. , 1996, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[58]  G. Semenza,et al.  Expression of hypoxia-inducible factor-1alpha: a novel predictive and prognostic parameter in the radiotherapy of oropharyngeal cancer. , 2001, Cancer research.

[59]  R. Gatenby,et al.  Oxygen distribution in squamous cell carcinoma metastases and its relationship to outcome of radiation therapy. , 1988, International journal of radiation oncology, biology, physics.

[60]  V. Grégoire,et al.  Preclinical validation of the hypoxia tracer 2-(2-nitroimidazol-1-yl)-N-(3,3,3-[18F]trifluoropropyl)acetamide, [18F]EF3 , 2004, European Journal of Nuclear Medicine and Molecular Imaging.

[61]  P. V. van Diest,et al.  HIF1-alpha overexpression indicates a good prognosis in early stage squamous cell carcinomas of the oral floor , 2005, BMC Cancer.

[62]  Matthias Reimold,et al.  Prognostic impact of hypoxia imaging with 18F-misonidazole PET in non-small cell lung cancer and head and neck cancer before radiotherapy. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[63]  F. O’Sullivan,et al.  Hypoxia and Glucose Metabolism in Malignant Tumors , 2004, Clinical Cancer Research.

[64]  M. Horsman,et al.  Measurement of tumor oxygenation. , 1998, International journal of radiation oncology, biology, physics.

[65]  A. Okamura,et al.  Prognostic significance of p53, Ki-67, VEGF and Glut-1 in resected stage I adenocarcinoma of the lung. , 2002, Lung cancer.

[66]  A. Harris,et al.  Tumour hypoxia, hypoxia signaling pathways and hypoxia inducible factor expression in human cancer. , 2001, Anticancer research.

[67]  K. Nishio,et al.  Osteopontin overproduced by tumor cells acts as a potent angiogenic factor contributing to tumor growth. , 2003, Cancer letters.

[68]  A. Harris,et al.  Advances in Brief Hypoxia-inducible Factors HIF-1 and HIF-2 in Head and Neck Cancer : Relationship to Tumor Biology and Treatment Outcome in Surgically Resected Patients , 2002 .

[69]  C. Aquino-Parsons,et al.  Comparison between the comet assay and the oxygen microelectrode for measurement of tumor hypoxia. , 1999, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[70]  M. Flentje,et al.  Glucose requirement for hypoxic accumulation of hypoxia-inducible factor-1α (HIF-1α) , 2005 .

[71]  R. Airley,et al.  Hypoxia-regulated glucose transporter Glut-1 may influence chemosensitivity to some alkylating agents: results of EORTC (First Translational Award) study of the relevance of tumour hypoxia to the outcome of chemotherapy in human tumour-derived xenografts. , 2005, International journal of oncology.

[72]  R. Fisher,et al.  Phase I trial of concurrent tirapazamine, cisplatin, and radiotherapy in patients with advanced head and neck cancer. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[73]  B. Teicher.  Hypoxia and drug resistance , 1994, Cancer and Metastasis Reviews.

[74]  P. Vaupel,et al.  Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects. , 2001, Journal of the National Cancer Institute.

[75]  A. Harris,et al.  Hypoxia-inducible factor (HIF1A and HIF2A), angiogenesis, and chemoradiotherapy outcome of squamous cell head-and-neck cancer. , 2002, International journal of radiation oncology, biology, physics.

[76]  B. Liang.  Effects of hypoxia on drug resistance phenotype and genotype in human glioma cell lines , 1996, Journal of Neuro-Oncology.

[77]  M. Dewhirst,et al.  Tumor oxygenation predicts for the likelihood of distant metastases in human soft tissue sarcoma. , 1996, Cancer research.

[78]  A. Harris,et al.  Hypoxia-regulated carbonic anhydrase-9 (CA9) relates to poor vascularization and resistance of squamous cell head and neck cancer to chemoradiotherapy. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[79]  W. Landuyt,et al.  The prognostic value of the hypoxia markers CA IX and GLUT 1 and the cytokines VEGF and IL 6 in head and neck squamous cell carcinoma treated by radiotherapy ± chemotherapy , 2005, BMC Cancer.

[80]  M Molls,et al.  Influence of the hypoxic subvolume on the survival of patients with head and neck cancer. , 1999, International journal of radiation oncology, biology, physics.

[81]  C. Koch,et al.  Hypoxic Heterogeneity in Human Tumors: EF5 Binding, Vasculature, Necrosis, and Proliferation , 2001, American journal of clinical oncology.

[82]  M. Gassmann,et al.  Induction of HIF–1α in response to hypoxia is instantaneous , 2001, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[83]  R. Wahl,et al.  Expression of hexokinase II and Glut-1 in untreated human breast cancer. , 2002, Nuclear medicine and biology.

[84]  Nagara Tamaki,et al.  Biologic correlates of intratumoral heterogeneity in 18F-FDG distribution with regional expression of glucose transporters and hexokinase-II in experimental tumor. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[85]  L. Bentzen.  Feasibility of Detecting Hypoxia in Experimental Mouse Tumours with 18F-fluorinated Tracers and Positron Emission Tomography: A Study Evaluating [18F]Fluoromisonidazole and [18F]Fluoro-2-deoxy-D-glucose , 2000 .